J&J prostate cancer drug improves survivalJohnson & Johnson's prostate cancer drug Zytiga improved survival in patients who had not received chemotherapy in a late-stage study, the company said on Thursday. An independent data monitoring committee unanimously recommended More… |
Family business survival rate highThe survival rate of second generation family businesses is 30 per cent while third and fourth generation family companies account for 15 per cent and 1 per cent to 2 per cent respectively. Survival chance for 100-year-old companies is on More… |